Tyra Biosciences Inc (TYRA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $25.24 (+3.32%), Market cap $2.20B, 52-week low–high $8.82 ~ $39.61.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven gen
Financial statements, price targets, institutional (13F) holdings and related news for Tyra Biosciences Inc are updated in real time on BlackAll Trade.
Tyra Biosciences Inc trades at $25.24 (+3.32%). Real-time quotes and charts are available on BlackAll Trade.
Tyra Biosciences Inc has a market cap of about $2.20B.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a preci